MAM
PDLI

Martingale Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Martingale Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-45,436
Closed -$363K – 1089
2013
Q3 		$363K Sell
45,436
-1,200
-3% -$9.65K 0.01% 844
2013
Q2 		$361K Buy
+46,636
New +$364K 0.01% 815

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Martingale Asset Management's PDLI Position: Q4 2013 in Review

Martingale Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2013, closing a stake of 45,436 shares — an estimated $363K sold.

Martingale Asset Management first reported a position in PDLI in Q2 2013 and held it in 2 quarters. The position peaked at $363K in Q3 2013. 224 funds tracked by Wall St. Rank hold PDLI as of Q4 2013.

  • Martingale Asset Management reported no remaining PDL BioPharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • Martingale Asset Management sold 45,436 PDL BioPharma, Inc. shares in Q4 2013, an estimated $363K.
  • Martingale Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 2 quarters.
  • Martingale Asset Management's PDL BioPharma, Inc. position peaked at $363K in Q3 2013.
  • 224 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2013.

Based on Martingale Asset Management's 13F filing for Q4 2013, filed 12 Feb 2014.